Denmark · Delayed Price · Currency is DKK Zealand Pharma Statistics
Total Valuation
Zealand Pharma has a market cap or net worth of DKK 20.87 billion. The enterprise value is 6.17 billion.
| Market Cap | 20.87B |
| Enterprise Value | 6.17B |
Important Dates
The next confirmed earnings date is Thursday, May 7, 2026.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zealand Pharma has 70.62 million shares outstanding. The number of shares has increased by 7.70% in one year.
| Current Share Class | 70.62M |
| Shares Outstanding | 70.62M |
| Shares Change (YoY) | +7.70% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 0.36% |
| Owned by Institutions (%) | 35.01% |
| Float | 56.77M |
Valuation Ratios
The trailing PE ratio is 3.28 and the forward PE ratio is 16.27.
| PE Ratio | 3.28 |
| Forward PE | 16.27 |
| PS Ratio | 2.27 |
| PB Ratio | 1.41 |
| P/TBV Ratio | 1.41 |
| P/FCF Ratio | 3.21 |
| P/OCF Ratio | 3.20 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 0.89, with an EV/FCF ratio of 0.95.
| EV / Earnings | 0.96 |
| EV / Sales | 0.67 |
| EV / EBITDA | 0.89 |
| EV / EBIT | 0.89 |
| EV / FCF | 0.95 |
Financial Position
The company has a current ratio of 23.57, with a Debt / Equity ratio of 0.03.
| Current Ratio | 23.57 |
| Quick Ratio | 23.20 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.06 |
| Debt / FCF | 0.06 |
| Interest Coverage | 238.04 |
Financial Efficiency
Return on equity (ROE) is 55.06% and return on invested capital (ROIC) is 1,401.57%.
| Return on Equity (ROE) | 55.06% |
| Return on Assets (ROA) | 33.97% |
| Return on Invested Capital (ROIC) | 1,401.57% |
| Return on Capital Employed (ROCE) | 45.26% |
| Weighted Average Cost of Capital (WACC) | 7.39% |
| Revenue Per Employee | 18.77M |
| Profits Per Employee | 13.15M |
| Employee Count | 501 |
| Asset Turnover | 0.72 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zealand Pharma has paid 546.06 million in taxes.
| Income Tax | 546.06M |
| Effective Tax Rate | 7.80% |
Stock Price Statistics
The stock price has decreased by -27.97% in the last 52 weeks. The beta is 0.57, so Zealand Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -27.97% |
| 50-Day Moving Average | 346.73 |
| 200-Day Moving Average | 413.51 |
| Relative Strength Index (RSI) | 46.06 |
| Average Volume (20 Days) | 444,234 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zealand Pharma had revenue of DKK 9.21 billion and earned 6.46 billion in profits. Earnings per share was 90.22.
| Revenue | 9.21B |
| Gross Profit | 9.21B |
| Operating Income | 6.92B |
| Pretax Income | 7.00B |
| Net Income | 6.46B |
| EBITDA | 6.93B |
| EBIT | 6.92B |
| Earnings Per Share (EPS) | 90.22 |
Balance Sheet
The company has 15.11 billion in cash and 405.77 million in debt, with a net cash position of 14.70 billion or 208.21 per share.
| Cash & Cash Equivalents | 15.11B |
| Total Debt | 405.77M |
| Net Cash | 14.70B |
| Net Cash Per Share | 208.21 |
| Equity (Book Value) | 14.83B |
| Book Value Per Share | 210.04 |
| Working Capital | 15.01B |
Cash Flow
In the last 12 months, operating cash flow was 6.53 billion and capital expenditures -33.37 million, giving a free cash flow of 6.50 billion.
| Operating Cash Flow | 6.53B |
| Capital Expenditures | -33.37M |
| Depreciation & Amortization | 9.95M |
| Net Borrowing | -20.16M |
| Free Cash Flow | 6.50B |
| FCF Per Share | 92.02 |
Margins
Gross margin is 99.99%, with operating and profit margins of 75.06% and 70.05%.
| Gross Margin | 99.99% |
| Operating Margin | 75.06% |
| Pretax Margin | 75.98% |
| Profit Margin | 70.05% |
| EBITDA Margin | 75.17% |
| EBIT Margin | 75.06% |
| FCF Margin | 70.52% |
Dividends & Yields
Zealand Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.70% |
| Shareholder Yield | -7.70% |
| Earnings Yield | 30.92% |
| FCF Yield | 31.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zealand Pharma has an Altman Z-Score of 21.93 and a Piotroski F-Score of 7.
| Altman Z-Score | 21.93 |
| Piotroski F-Score | 7 |